A STUDY EVALUATING PERTUZUMAB (PERJETA) COMBINED WITH TRASTUZUMAB (HERCEPTIN) AND STANDARD ANTHRACYCLINE-BASED CHEMOTHERAPY IN PARTICIPANTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-POSITIVE LOCALLY ADVANCED, INFLAMMATORY, OR EARLY-STAGE BREAST CANCER: